- Home
- IPHA vs VIGL Comparison
IPHA vs VIGL Comparison
Compare IPHA & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- VIGL
- Stock Information
- Founded
- IPHA 1999
- VIGL 2020
- Country
- IPHA France
- VIGL United States
- Employees
- IPHA N/A
- VIGL N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- VIGL Health Care
- Exchange
- IPHA Nasdaq
- VIGL Nasdaq
- Market Cap
- IPHA 173.6M
- VIGL 141.1M
- IPO Year
- IPHA 2019
- VIGL 2022
- Fundamental
- Price
- IPHA $2.31
- VIGL $3.42
- Analyst Decision
- IPHA Strong Buy
- VIGL Buy
- Analyst Count
- IPHA 1
- VIGL 5
- Target Price
- IPHA $11.50
- VIGL $16.60
- AVG Volume (30 Days)
- IPHA 5.4K
- VIGL 118.4K
- Earning Date
- IPHA 09-12-2024
- VIGL 08-13-2024
- Dividend Yield
- IPHA N/A
- VIGL N/A
- EPS Growth
- IPHA N/A
- VIGL N/A
- EPS
- IPHA N/A
- VIGL N/A
- Revenue
- IPHA $68,134,188.00
- VIGL N/A
- Revenue This Year
- IPHA N/A
- VIGL N/A
- Revenue Next Year
- IPHA $105.84
- VIGL N/A
- P/E Ratio
- IPHA N/A
- VIGL N/A
- Revenue Growth
- IPHA 6.88
- VIGL N/A
- 52 Week Low
- IPHA $1.81
- VIGL $2.47
- 52 Week High
- IPHA $3.15
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- IPHA 53.25
- VIGL 46.18
- Support Level
- IPHA $2.14
- VIGL $3.20
- Resistance Level
- IPHA $2.35
- VIGL $3.78
- Average True Range (ATR)
- IPHA 0.14
- VIGL 0.30
- MACD
- IPHA 0.00
- VIGL 0.03
- Stochastic Oscillator
- IPHA 61.76
- VIGL 36.67
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.